1-7 of 7
Wei Meng
Close
Sort by
Journal Articles

IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

Keshu Zhou, Yuqin Song, Tienan Yi, Shuling Hou, Xingchen Liu, Ningjing Lin, Tingting Du, Xing Zhao, Xiaobo Wu, Xiwen Zhao, Wei Meng, Wencheng Xu, Qiying Lu, Wenzhi Tian, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 609.
https://doi.org/10.1182/blood-2023-174829
Published: 2023
Journal Articles

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Margery Gang, Nancy D. Marin, Pamela Wong, Carly C. Neal, Lynne Marsala, Mark Foster, Timothy Schappe, Wei Meng, Jennifer Tran, Maximilian Schaettler, Marco Davila, Feng Gao, Amanda F. Cashen, Nancy L. Bartlett, Neha Mehta-Shah, Brad S. Kahl, Miriam Y. Kim, Matthew L. Cooper, John F. DiPersio, Melissa M. Berrien-Elliott, Todd A. Fehniger
Journal: Blood
Blood (2020) 136 (20): 2308–2318.
https://doi.org/10.1182/blood.2020006619
Published: 2020
Includes: Supplemental data
Journal Articles

MiR-144 Targets APP to Regulate AML1/ETO+ Leukemia Cell Migration Via p-ERK/c-Myc/MMP-2 Pathway

Fanyi Meng, Ling Jiang, PhD MD, Wei Meng, PhD, Guo-Pan Yu, MD, Yin Changxin, Zhixiang Wang, PhD, Xuejie Jiang, MD, Qifa Liu
Journal: Blood
Blood (2017) 130 (Supplement 1): 5093.
https://doi.org/10.1182/blood.V130.Suppl_1.5093.5093
Published: 2017
Journal Articles

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

Clinical Trials & Observations
Cristina Correia, Paula A. Schneider, Haiming Dai, Ahmet Dogan, Matthew J. Maurer, Amy K. Church, Anne J. Novak, Andrew L. Feldman, Xiaosheng Wu, Husheng Ding, X. Wei Meng, James R. Cerhan, Susan L. Slager, William R. Macon, Thomas M. Habermann, Judith E. Karp, Steven D. Gore, Neil E. Kay, Diane F. Jelinek, Thomas E. Witzig, Grzegorz S. Nowakowski, Scott H. Kaufmann
Journal: Blood
Blood (2015) 125 (4): 658–667.
https://doi.org/10.1182/blood-2014-04-571786
Published: 2015
Includes: Supplemental data
Journal Articles

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

Husheng Ding, Jennifer Hackbarth, Paula A. Schneider, Kevin L. Peterson, X. Wei Meng, Haiming Dai, Thomas E. Witzig, Scott H. Kaufmann
Journal: Blood
Blood (2011) 118 (18): 4872–4881.
https://doi.org/10.1182/blood-2011-02-334870
Published: 2011
Includes: Supplemental data
Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Clinical Trials & Observations
Judith E. Karp, Karen Flatten, Eric J. Feldman, Jacqueline M. Greer, David A. Loegering, Rebecca M. Ricklis, Lawrence E. Morris, Ellen Ritchie, B. Douglas Smith, Valerie Ironside, Timothy Talbott, Gail Roboz, Son B. Le, Xue Wei Meng, Paula A. Schneider, Nga T. Dai, Alex A. Adjei, Steven D. Gore, Mark J. Levis, John J. Wright, Elizabeth Garrett-Mayer, Scott H. Kaufmann
Journal: Blood
Blood (2009) 113 (20): 4841–4852.
https://doi.org/10.1182/blood-2008-08-172726
Published: 2009
Includes: Supplemental data
Journal Articles

A Directly Spliced Exon 10–Containing CD44 Variant Promotes the Metastasis and Homotypic Aggregation of Aggressive Non-Hodgkin's Lymphoma

Yoshihiro Yakushijin, Joshua Steckel, Samir Kharbanda, Robert Hasserjian, Donna Neuberg, Wei-meng Jiang, Ian Anderson, Margaret A. Shipp
Journal: Blood
Blood (1998) 91 (11): 4282–4291.
https://doi.org/10.1182/blood.V91.11.4282
Published: 1998